Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

NLW CV 2016

880 views

Published on

  • Be the first to comment

  • Be the first to like this

NLW CV 2016

  1. 1. Dr. Nancy Louis Wassef | Curriculum Vitae Reading, Berkshire | +44 (0) 7901 710 243 | nancywassef54@gmail.com IFCAP, CSci, FRCPath 1 (eq) , MSc, MB BCh UK General Medical Council Registered # 6153962,HCPC registered: CS 18393
 International Fellow of College of American Pathologists and Member of American Chemical Society (ACS), Member of the Royal College of Pathologists, London, UK (# 0998323),Member of Royal Society of Medicine, London, UK (#00622002),Member of Association of Clinical Biochemists, London, UK (#09395), Registered as Consultant Clinical and Chemical Pathology, Reg. # 732, 1999,Egyptian Medical Syndicate, Cairo-Egypt, Highly skilled and respected Medical Doctor and International Clinical Manager with excellence in clinical operations and team management in prestigious institutions in the UK and beyond. Excellence in strategic development of all needs-based medical education programs with executive management and Collaborate with executive-level management and departmental directors in long-term project production planning to achieve global company goals. More than thirty years experience managing laboratories and involvement in evaluation and implementation of new procedures and equipment for various laboratory sections. Published in over thirty medical papers in the fields of Plasma Cell Dyscrasia, Inflammatory Proteins, Amyloidosis, Vitamin D and Thyroid Disease. Fluent in English, French and Arabic with extensive experience working and living abroad. AREAS OF STRENGTH  Clinical Pathology  Chemical Pathology  Microbiology  Hematology  Blood Transfusion Medicine  Infection Control Processes  Laboratory Management  External Quality Assessment Schemes  Recruitment & Training  Communication Skills  Interpersonal Skills  Presentation Skills  Clinical Support Services  Business Development  Scientific Marketing  Scientific Assay Development & Evaluation  Quality Control PROFESSIONAL EXPERIENCE 1.2015-5.2015 International Clinical Manager Helena Biosciences, Europe 2007-2015 Head of Proteins & Enzymes, Principal Clinical Scientist, Clinical Biochemistry Dept. Royal Free Hospital, London 1989 - 2004: Clinical Pathologist and Director of PathologyServices and Blood Bank, Head of Infection Control Committee. GNP Hospital, Jeddah, KSA 1985 - 1986: Specialist Clinical & Chemical Pathologist Al Ali General Hospital, Riyadh, KSA 1979-1983: Doctor of Blood Transfusion and Laboratory Medicine Ain Shams University Hospitals, Cairo
  2. 2. Dr. Nancy L. Wassef | Curriculum Vitae Page 2 PROFESSIONAL EXPERIENCE 1.2015-5.2015 International Clinical Manager Helena Biosciences, Europe  Lead customer clinical support services both internationally and within the UK by providing clinical training programs and promoting Helena’s flagship.  Developed and secured new Helena business internationally and within the UK. 
  Facilitated the completion, clinical readiness, launch and installation of Helena’s major new products portfolio  Developed and completed scientific marketing, training literature and scientific publications for all of Helena’s new and competitive product lines to increase domestic and international sales. 2007-2015 Head of Proteins & Enzymes, Principal Clinical Scientist, Clinical Biochemistry Dept. Royal Free Hospital, London  Responsible for day-to-day comprehensive management, operation, supervision and direction of the specialist service provided by the Protein and Enzymes department. 
  Consulted and liaised with clinicians and senior medical staff on the complex interpretation of biochemistry results and especially on differential diagnoses and monitoring treatment by participating in DUTY OFFICERS rotas once every 7-10 days. 
  Trained and taught four trainee clinical scientists within the section. 
  Formed and lead the Training committee and initiated a series of weekly 
 departmental seminars titled "back to basics " for all biochemistry staff. 
  Main coordinator in EuLite and Alchemy trials.  In 2008 and 2011,covered colleague’s maternity leave as the Head of Endocrine and RIA Section in addition to my responsibilities in the Proteins laboratory (see duties in Endocrine Section paragraph) 
 Duties & Responsibilities as Head of Proteins & Enzymes  Lead the second busiest unit in the hospital’s department, which has a vital role in supporting the diagnostic services and results interpretation the several critical hospital departments. 
  Acted as head of five principal work streams/assays: 1) electrophoresis 2) nephelometry 3) glycated haemoglobin 4) vitamin D 5) immulite assays  Also acted as head of smaller volume, more frequently scheduled assays, which included but was not limited to 17OH Progesterone by RIA and Urinary Free Cortisol.  Accountable for the quality assuranceof the aforementioned tests including external assessment and internal monitoring, taking corrective action where the need is identified. 
  Responsible for the direction, supervision and management as well as teaching and training of scientific and technical staff working within the section. 
  Initiated and participated in clinical audits pertinent to the provision of the clinical biochemistry service within and without the department. 
  Introduced and validated Serum Amyloid A assays in2009 and Capillary Zone
  3. 3. Dr. Nancy L. Wassef | Curriculum Vitae Page 3 Electrophoresis method in 2011. 
  Evaluated and introduced the Hevylite assay and assessed its clinical significance if offered in our test repertoire. 
  Evaluated the N- Latex free light chain method of Siemens and comparing its performance against the Binding Site assay. (See Poster in IFCC EuroMedlab Milan 2013) 
  Promoted and maintained close links with appropriate clinical departments and teams by participating in National Amyloidosis Centre and Haematology MDT meetings. 
  Reported and authorised results of protein and urine, Isoenzymes electrophoresis as well as Free light chain and SAA. 
  Ensured that management and operational performance data (KPI) is monitored, for example, turnaround times, workload and materials consumption and take corrective action where necessary. 
  Troubleshot and organised appropriate corrective action when there is a situation, which may or has caused a service delivery failure. 
  Maintained a system of records and documentation keeping for routine and research work. Ensured all staff in the section kept records and Standard Operating Procedures up-to-date, and that all records and documentation are maintained properly within a Total Quality management system in order to maintain our CPA/ UKAS full accreditation status. 
  Held regular section meetings in order to communicate and update staff with changes within the section, the department as well as Trust wise. 
  Disseminated knowledge gained during private study or research and developed projects through presentation at local, national and international meetings and publications. 
 ) 
  Fire Warden and Deputy Health and Safety Officer of the department. 
  Organised the first North London International Scientific Meeting (CPD accredited) to talk about Laboratory Perspectives in the diagnosis of Plasma Cell and B Lymphoid Dyscrasias 
 Duties as Head of Endocrine & RIA Section Responsible for the day-to-day comprehensive management, operation, supervision and direction of the specialist service provided by the Endocrine and RIA sections. 
  Specialised tests performed on site: Growth Hormone, IGF1 and Androstenedione on Immulite 1000,17 Hydroxy progesterone, Vitamin D and Renin (RIA), Urine free Cortisol and Macroprolactin. 
  Authorised and interpreted results of Thyroid function tests, Sex hormones, Parathyroid Hormone and Tumour markers. 
  Liaised with clinicians in hospital and with GPs, discussingand interpreting different endocrine results (sex hormones, Thyroid functions) as well as Dynamic function tests such as synacthen and Growth hormone/ glucose tolerance. 

  4. 4. Dr. Nancy L. Wassef | Curriculum Vitae Page 4  Introduced and evaluated Vit D assay ( chemiluminescence method) on the Liaison platform due to significant in increase in workload justifying the stopping of the manual RIA method. Renin was also discontinued on site since workload figures did not justify the health and safety risks undertaken to run RIA test. 
  Wrote the Vit.D standard operating procedure as well as reviewed those of UFC and Growth hormone. 
  Attended Thyroid clinic once a week. 
  Performed Heterophile antibodies on sera of patients suspected to have thyroid resistance as part of authorising results and helped the Section BMS2 in writing the SOP. 
 
  Monitored the quality control of section and ensured that appropriate corrective actions were taken when there was a situation which may or had caused a service delivery failure.
  Analysed data from External Quality Assessment Schemes such as NEQAS and communicated performance, as well as took the necessary action when required. 
  Ensured that management and operational performance data were monitored including turnaround times, workload and materials consumption and to take corrective action where necessary. 1989 - 2004: Clinical Pathologist and Director of PathologyServices and Blood Bank, Head of Infection Control Committee. GNP Hospital, Jeddah, KSA GNP Hospital, where I worked previously for the last 16 years, is a Private sixty beds’ hospital with A&E and an Outpatient Department including Diabetes and Obesity clinics. It had many specialities including Endocrinology, Cardiology, Paediatrics, Gastroenterology, as well as Obstetrics and Gynaecology, ENT, and general Surgery Departments. The Clinical Laboratory that I headed included Clinical Chemistry, Microbiology, Serology, Haematology and Blood Transfusion sections.  The Hospital and the laboratory were recognised as referral centres for ALL British and American expatriates, as well as for British, Canadian and Australian Consulates pre-immigration laboratory works.  I was directly reporting to the Clinical Medical Director of the hospital as Head of Pathology Department.  I orchestrated a multi-disciplinary team comprising a laboratory registrar (M.B.B.Ch) under training, one BMS-2 and six BMS -1, two MLAs and a secretary. The lab was run on an 8hours shift basis, 24 hours a day, 7 days a week. We performed approximately 8000-10,000 clinical biochemistry tests monthly.  Since I started, I initiated the laboratory automation and expansion from a small sized lab to a medium workload one.  When I started in GNP Polyclinic, the laboratory had only a small Coulter analyser (5 parameters),one Vitros DT 60, Dry chemistry , a Quantum analyzer (Abbott) for HIV serology and Microbiology work was manual. There was no Blood transfusion.  Being in charge of the lab, I championed its upgrade to a medium sized lab suitable for a 60 bed Hospital. I introduced and validated the following tests and methods: Axsym system for Endocrinology, Tumour and Cardiac markers (TFT, sex hormones, Prolactin,Troponin, BNP, Ca125, CEA, PSA, FPSA) as well as other infectious immunoassays such as HIV, Hepatitis antigens and antibodies ,Cytomegalovirus and Infectious Mononucleosis Serology.
  5. 5. Dr. Nancy L. Wassef | Curriculum Vitae Page 5 IMX-Abbott, on which we ran HbA1c samples, and was the back up for Chemistry as Vitek 32 (Biomerieux) was for serology tests. Growth hormone and IgF1 were referred to Bioscientia, CAP accredited-Germany, since workload was not cost justified. Vitros 950 (Johnson & Johnson) which was replaced later by VitrosFusion (Johnson & Johnson) for routine Clinical chemistry. Vitros 250 (Johnson & Johnson) was the backup instrument. ABL5 gas analyzer Clinitek for urine strips. Additionally I introduced I Stat - Abbott diagnostics as point of care devices Advia 120 and Coulter HMX for Haematology routine full blood count. Electra 1400 Hemoliance for coagulation studies. Minividas (Biomerieux) for API system for microbiological isolation and identification of different micro-organisms. Dia Med system for Blood transfusion.  The Laboratory participated in an External Quality Assessment scheme through Biorad and IQC were strictly run daily following Westgard rules.  Esoteric tests and other tests not performed on site were referred to CAP accredited Bioscientia referral laboratory in Germany. These included Protein Electrophoresis, A1AT phenotype and genotype, BRCA-I & II and others. Experience in Chemical Pathology:  Reported and authorised 250-300 Multidisciplinary report s per day for patients attending our outpatients clinics and in-patients.  Since Inborn errors of metabolism features largely in Saudi Arabia and I frequently consulted with paediatricians and specialists in problematic cases .  Consequently I was first to introduce the screening programme for Neonatal Hypothyroidism and PKU deficiency in GNP hospital.  I started the pre marital full check up and screening for hereditary and inborn errors of metabolism in the hospital since Co-sanguinous marriage is prevalent in the gulf area and Middle East.  I had access and discussions,on a regular basis, with Consultants from King Abdul Aziz University (KAU), Jeddah, who have special interests in the diagnosis and management of hyperlipidaemia.  Diabetes features very predominantly in Saudi Arabia, and I have been involved in the choice and implementation of point of care devices (I Stat - Abbott diagnostics, and Clinitek-Bayer Diagnostics) for the diabetic population who visited the clinics.  I also worked with two consultants with interests in Endocrinology and advised them especially on interpretating Thyroid function tests and differential diagnosis of problematic cases of Amenorrhea and hirsutism.  I liaised with all the Hospital departments as well as others outside the Hospital  I took part regularly in club meetings hosted on a rotational basis with the hospitals in Jeddah. Management and Administrative responsibilities:  I had the responsibility for the financial management of the laboratory. This included the evaluation of appropriate fiscal measures to ensure effective laboratory use.  I also encouraged a discriminating use for the laboratory resources with the clinicians by providing advice to clinical staff on the use, choice of tests and interpretation of results on patients with endocrine and lipid disorders.  I held departmental weekly meetings with laboratory staff to discuss Health and Safety matters, quality assuranceprogram as well as any clinical incident report.  I held regular monthly meetings with clinical staff and liaised with different departments in the hospital to ensure appropriate and rational use of the laboratory through auditing.
  6. 6. Dr. Nancy L. Wassef | Curriculum Vitae Page 6  I attended to regular meetings in Jeddah and Egypt as Continuing Professional Development as well as in the Royal College of Pathologist  I coordinated teaching programs for technical and nursing staff regarding Health and Safety, Infection Control and any other scientific advances in the laboratory.  I encouraged continuing professional development of laboratory personnel and held fortnightly seminars in the laboratory to discuss different analytes, their use and pitfalls of their measurements.  Engaged in teaching and training King Abdul Aziz University students of Biochemistry  I initiated, wrote and maintained Standard Operating Procedures Manuals for All Laboratory analytes and procedures.  Participated in Saudi Western Region Quality Programme (MRQP), organised by the Ministry of Health (KSA), as Quality Coordinator.  The Laboratory under my management was accredited by Bioscientia, Germany, having met all the international medical standards as duly authorized Referral Laboratory.(see Certificate) Experience in Haematology and Blood Transfusion Medicine:  Provided advice on all cases of Haematology, diagnosing and coordinating with other colleagues in the treatment of benign haematology cases as well as running The Coagulation clinic.  Blood film Morphological Assessment and Malaria screening.  Referring any cases suspected of haematological malignancy or plasma cell Dyscrasia to Specialised Centres within the Kingdom.  Blood Bank Director for 15 years, screening 1000 donors per year and supervising bleeding processes, adhering to strict Saudi Ministry quality standards adapted from Standards of the American Association of Blood Banks.Initiated Quality Assessment Programme within separate component preparation units, utilising DiaMed system.  High volume of liaison with Blood Bank Supervisor, resolving problematic cases.  Reviewed all transfusion reactions and initiated / implemented procedures for blood usage as integral member of Hospital Transfusion Committee. 1986 -1989: Maternity leave & careerbreak (in Paris). 1985 - 1986:Specialist Clinical & Chemical Pathologist Al Ali General Hospital, Riyadh, KSA  208 beds’ private hospital.  I performed Clinical Pathologist work mainly in Clinical Biochemistry.  initiated the Standard Operating Procedures of the laboratory.  I assisted the clinicians in requesting their tests and helped them in reaching diagnosis, especially in renal and internal medicine clinics.  Helped the Hospital’s Dutch management in recruiting doctors from different specialities. 5.1985 to 8.1985:Trainee Chemical Pathology Erfan & Bagedo General Hospital, Jeddah, KSA Erfan & bagedo Hospital is a private tertiary hospital. The hospital runs 24 hours services, 7 days a week with an Emergency 24 hours service  Daily outpatient census range from 1,600 to 1,800 patients.  Daily inpatient census is 170 to 200 patients.  While training there, under the supervision of Dr Baher Saad Badawi, FRCPATh and Director of laboratories, I gained a good grasp of the clinical aspects of different diseases and their differential diagnosis through proper laboratory results’ interpretation.  Acquired experience in different diagnostic techniques and principles of a wide range of analytical equipment in the laboratory, for routine Chemistry, Endocrinology, Haematology and Infectious diseases.
  7. 7. Dr. Nancy L. Wassef | Curriculum Vitae Page 7  Dealt with different analytical instruments: Kodak DT60, Ektachem 250,Cobas-Bio, SMA analysers, Quantum, Axsym, Coulter &Cell dyne.  Gained an excellent concept of laboratory External Quality Assessment and participated in various workshops regarding this subject.  Assisted training and teaching of newly assigned doctors & technicians.  Participated in the ward rounds such as Paediatric& Diabetic clinics as well as worked and interpreted the results of blood gas analysis in ICU. From Dec.1984 to Apr.1985: Career Break (KSA). From May1983 to Nov.1984: Study Leave to prepare for MSc project and exams. Title: Measurement of Free Erythrocyte Protoporphyrin in Children with Microcytosis. 1979-1983: Doctor of Blood Transfusion and Laboratory Medicine Ain Shams University Hospitals, Cairo  I worked as Doctor of blood transfusion and Laboratory while studying for my Master degree in Clinical and Chemical Pathology.  In addition to my work in Ain Shams University Hospitals, I spent a mandatory time of 2 years and attended to lectures and practical sessions in the disciplines of general chemical pathology laboratories gaining experience with different photometers, spectrophotometers, ASTRA analyzer, electrophoresis unit, and ICU, as well as diabetic and paediatric clinics where patients came on a day-care basis, for examination, follow up and treatment.  I participated in teaching and training postgraduates assigned to the hospital’s general laboratories and attended to various lectures and workshops during the period of my training.  I learned and applied fundamental statistical concepts as well as Quality management and how to appropriately use laboratory data with Prof. Samir Hanna Sadek, FRCPATH.  I learned and gained practical experience in principles of automation and instrumentation, including general laboratory techniques and procedures, supplies, volumetric equipment, and units of measurements with Prof. Laila Osman .  I learned and got trained on how to establish and use reference values as well as evaluating new methods to introduce in the laboratory Quality assurance and management.  Specimen collection and processing and gaining experience in the sources of biological variation.  I covered mostly all theoretical areas of Chemical Pathology including management, Quality Control, Carbohydrates, Lipids, Proteins , Enzymes, Calcium and phosphate metabolism Nitrogen metabolites and renal function, liver functions, gastric pancreatic and intestinal function and Biochemical aspects of Haematology  I rotated in all areas of practical chemical pathology as follows: Routine Clinical Chemistry laboratory, Proteins electrophoresis Unit, Emergency Laboratory, Endocrinology Unit, Immunology Section, Electrolytes and blood gases in ITU and finally therapeutic drug monitoring and analysis of toxic substances in our newly opened, then, Toxicology and Forensic Unit. TRAINING COURSES & MEETINGS 2015  Egyptian Society of laboratory Medicine International Conference,Cairo, April 2015  Training Staff and Distributors worldwide on CZE, Immunofixation and Immunodisplacement interpretation
  8. 8. Dr. Nancy L. Wassef | Curriculum Vitae Page 8  Arab Health Exhibition, Dubai, January 2015 2014  Leadership in Healthcare Training Course, Oct.2013 - July,2014 , Royal Free Hospital.  International User Group (Helena),Barcelona, September 2014  Sebia Users’ Group meeting, Birmingham, September 2014  Helena Education Day, York, May 2014  Egyptian Society of laboratory Medicine International Conference,Cairo, April 2014  6th UK Amyloidosis Network Workshop, Royal Free Hospital, London, February 2014  Arab Health Exhibition, Dubai, January 2014 2013 ▪ International User Group (Helena), Paris, October 2013 ▪ Myeloma Amyloid day, RSM, London September 2013 ▪ 20th IFCC- EFLM European Congress of Clinical chemistry, Milan,May 2013 ▪ 5th UK Amyloidosis Network Workshop, Royal Free Hospital, London, February 2013 2012  Laboratory Perspectives in the Diagnosis of Plasma Cell Dyscrasias, Royal Free Hospital, London, June 2012  Body Weight Management, Facts and Myths, Royal Free Hospital, London, March 2012  Analytical Investigations into Inherited Metabolic Disease, Royal Free Hospital, London, February 2012  Vitamin D in Kidney Stone Formers, Royal Free Hospital, London, January 2012  Trimethyaminuria, Royal Free Hospital, London, January 2012 2011  Design and Analysis of Studies in Healthcare, UCLH, London, September 2011  AST: Should we remove it from the LFT Profile, Royal Free Hospital, London, September 2011  Steroids and the Stress Response, Royal Free Hospital, London, January 2011  ACB Spotlight, Controversies & Changes in Immunoglobulins, RCPATh, London, 2011  IRR99 Training, Royal Free Hospital, London, 19 July 2011  Chemical Awareness and Emergency Spill Response, Royal Free Hospital, London, 5 July 2011  Capillary Electrophoresis Training , Sebia UK, June 7-8, 2011  Presented : “Unexpected Haemoglobin A1c Results” Royal Free Hospital, London, May 2011  POCT at the Royal Free, Royal Free Hospital, London, May 2011  Endocrinology Investigations, Royal Society of Medicine, London, May 2011  Low Potassium: How to investigate, Royal Free Hospital, London, March 2011  Multiple Myeloma: Review of Guidelines, Royal Free Hospital, London, March 2011  Introduction to Informative Governance, DoH, online training, London, March 2011  The Role of Caldicott/IG Lead in General Practice, DoH, online training, London, March 2011  Low Sodium: How to investigate, Royal Free Hospital, London, March 2011  Clinical Cases Presentation, Royal Free Hospital, London, March 2011  FH- National Audit Site Report, Royal Free Hospital, London, February 2011  Competent Persons (General Risk Assessors) Seminar, Royal Free Hospital, London, February 2011  Updated Chest Pain Protocol, Royal Free Hospital, London, January 2011 2010  BNII Training, Siemens, Frimley Park, UK,, December 2010  Clinical Applications of Serum Free Light Chains, Bath, September 2010
  9. 9. Dr. Nancy L. Wassef | Curriculum Vitae Page 9  Business Process improvement Workshop, Roche, Burgess Hill, June 2010 Siemens  Academy Laboratory Managers', Manchester June2010  Managing change Workshop, Roche, Burgess Hill, May 2010  ICPMS-What, Why, Where, How and When, Royal Free Hospital, London, May 2010  A guide to EQA, Royal Free Hospital, London, April 2010  Training on BN ProsPec instrument, Siemens,Frimley Park, UK, March 2010  Portfolio of instruments, Royal Free Hospital, Clinical Biochemistry, March 2010 2009  Recent Advances in the Management of Free Light Chain Disease, Ashford, May 2009  NeuroEndocrine Tumour Markers, Royal Free Hospital, London, May 2009  Modernising Scientific Careers, Royal Free Hospital, London, April 2009  Clinical Audit, Royal Free Hospital, London, April 2009  Glucose Audit, Royal Free Hospital, London, March 2009  Reagents Inventory Management schemes, Royal Free Hospital, London, March 2009  GCP in a nutshell, Royal Free Hospital, London, March 2009  Cryoglobulins, a very British case, Royal Free Hospital, London, February 2009  Screening for Novel components of Intracellular Signalling pathways, Royal Free Hospital, London, February 2009 2008  Customer awareness programme, Royal Free Hospital, London, December 2008.  MedScape online CME, London, November 2008  Lessons from the Jupiter Study: Statins moving to another planet? Royal Free Hospital, London, November 2008.  Thyroid Audit, Royal Free Hospital, London, October 2008.  The Role of Vitamin D in COPD, Royal Free Hospital, London, September 2008.  Aspects of HbA1c and Haemoglobinopathies, Keble College, Oxford, September 2008.  Promoting clinical Governance through effective Management course, Royal Free Hospital, London, July 2008  ACB Management and Leadership Course, University of Surrey, School of Postgraduate Medical Education, June 2008.  EQMS System Overview, Royal Free Hospital, London, June 2008  Cardiovascular risk assessment in HIV patients attending a designated lipid clinic, Royal Free Hospital, London, June 2008  The role of biochemical monitoring in renal failure and dialysis, Royal Free Hospital, London, June 2008  Evidence based Endocrinology, London, RSM, May 2008.  Festschrift for Paul Sweny, Royal Free Hospital, London, May2008  Diagnosis of Phaeochromocytoma, Royal Free Hospital, London, March 2008.  Primary Hyperoxaluria, Royal Free Hospital, London, February 2008.  Serum Free Light Chain Assay and monoclonal gammopaties, Royal Free Hospital, London, February 2008.  Mitochondrial disorders for the non initiated, London, RSM, January2008. 2007  Preliminary results of Urgents audit symposium, Royal Free Hospital, London, December 2007.  NT-BNP and Amyloidosis symposium, Royal Free Hospital, London, November 2007.  Natural Evolution and Engineering of Transketolase, Royal Free Hospital, London, November 2007.  Critical issues in Cardiovascular risk management, London, RSM, September 2007.  Clinical aspects for Protein Assays, and workshop,Royal Holloway College, University of London, September 2007.  Aspects of HbA1c and Haemoglobinopathies, Keble College, Oxford, July 2007.
  10. 10. Dr. Nancy L. Wassef | Curriculum Vitae Page 10  What’s New in Immunology, Birmingham, May 2007.  Using Electrophoresis Techniques to Their Full, Warwickshire, March 2007.  Diagnosis of Lysosomal Storage Disorders in The Enzyme Laboratory, Royal Free Hospital, London, February 2007. 2006  Quality Management Systems and Internal Auditing in the Clinical Pathology Laboratory, One day training course, Royal Free Hospital, London, November 2006. 2004  Total Quality Management in Health Care, Training course and workshop King Abdul Aziz University, Jeddah, Saudi Arabia, March 2004.  International Blood Transfusion Medicine Symposium, King Abdul Aziz University, Jeddah, Saudi Arabia, March 2004.  Pall Quality control of Blood Components Workshop. King Abdul Aziz University, Jeddah, Saudi Arabia, March 2004.  Obesity & Diabetes- A Regional Epidemic Symposium Arab Health Exhibition, Dubai UAE, January 2004. Earlier  Transfusion Medicine Symposium Erfan & Bagedo Hospitals, Jeddah, Saudi Arabia, March 2003.  Intensive Course in Post-graduate Haematology under the Auspices of the Royal College of Pathologists, London. King Abdul Aziz University, Jeddah, Saudi Arabia, October 2002.  Recent Advances in Clinical Laboratory Medicine Royal College of Pathologists, Jeddah, Saudi Arabia, October 2002.  Understanding Metabolic Medicine Royal College of Pathologists, London, September 2002.  What Cardiologists expect from The Laboratory Symposium Erfan & Bagedo Hospitals, Jeddah, Saudi Arabia, and January2002.  Laboratory Quality Assurance Workshop King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, October 1998.  Laboratory Quality Assurance, King Faisal Specialist Hospital, Riyadh, KSA, October 1998  Advances in Laboratory Medicine, King Khalid National Guard Hospital, Jeddah, KSA, January 1994  A Short Refresher Course on Infectious Diseases, King Khalid National Guard Hospital, Jeddah, KSA, February 1993 ABSTRACTS & PUBLICATIONS Heavy/Light Chain immunoparesis as a Novel Marker of Poor Outcomes in Systemic AL Amyloidosis. Sajitha Sachithanantham,Oscar Berlanga, Azra Alvi, Nancy Wassef, et al. (E1278) E-Poster Presentation,EHA Learning Center. Wechalekar A. Jun 12, 2015;99974 Correlation of IgA and IgM heavy chain/ light chain immunoassays with nephelometric total immunoglobulin measurements. Abeba Tekle, Sara Edwards, Ashraf Ghahani,Mayuri Patel, Jenna Lee, Lisa Mennie, Glenn O’Garro, Daniaal Dedat, Nancy Wassef
 Poster in the Proceedings of "Clinical Applications of Free Light Chain and Heavy/ Light Chain analysis’ conference, Edinburgh, April 2015 An Enigmatic Paraprotein SN Colyer, N Wassef
 Poster in the Proceedings of the 3rd EFLM-UEMS Congress, Liverpool,UK, October 2014 Heavy/Light Chain Characteristics in Patients with Localised Amyloidosis Sajitha Sachithanantham, Oscar Berlanga,
  11. 11. Dr. Nancy L. Wassef | Curriculum Vitae Page 11 Stephen Harding, Shameem Mahmood, Nancy Wassef, et al. . Poster in the Proceedings of XIVth International Symposium on Amyloidosis, USA, April 2014 Heavy/light chain-pair suppression as a novel marker of poor outcomes in systemic AL amyloidosis Sajitha Sachithanantham,Oscar Berlanga, Stephen Harding, Shameem Mahmood, Nancy Wassef, et al. Poster in the Proceedings of XIVth International Symposium on Amyloidosis, USA, April 2014 Clinical Comparison of Polyclonal and Monoclonal antibody based FLC assay for staging disease in systemic AL Amyloidosis
 Nancy L Wassef, Oscar Berlanga, Shameem Mahmood, et al.
 Poster in the Proceedings of XIVth International Symposium on Amyloidosis, USA, April 2014 A 20 year single centre experience of AA amyloidosis demonstrating changes in its epidemiology Helen J Lachman, JD Gillmore, Ashutosh D Wechalekar, S.D.Gibbs, Janet Gilbertson,Jenny Pinney, F.T.Hunt,,Dorota Rowczenio, Hadija Trojer, T. Lane, C. P. Venner,Sanjay M Banypersad, D. Gopaul David F Hutt ,Nancy Louis Wassef , M. B. Pepys , P. N. Hawkins Annals of the Rheumatic Diseases (Impact Factor: 9.27). 01/2014;71(Suppl 3): 283-284.DOI: 10.1136/annrheumdis- 2012-eular.2344 Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers Nancy Wassef, Thirusha Lane, Stephen Poole, Yogesh Mistry, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins and Mark B. Pepys Circ Res. 2014;114:672-676 An EnIgMatic Paraprotein Colyer SN, Wassef N , Nephrology Amyloidosis Day, RSM, London, September 2013 Comparison of the analytical performance of the polyclonal antibody based Freelite and monoclonal antibody based N Latex FLC assays in the detection of multiple myeloma and AL amyloidosis Wassef, N.L Poster in the Proceedings of IFCC EuroMedlab Milan, May 2013 Utility of Heavy/Light chain ratio in patients with systemic AL amyloidosis Berlanga O, Wassef N, et al.
 Poster in the Proceedings of IFCC EuroMedlab Milan 2013 Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. J Am Heart Assoc. 2013 Apr 22;2(2):e000098.doi: 10.1161/JAHA.113.000098. The role of immunological assessment in patients with acute kidney injury and possible myeloma Nancy L Wassef, Helen J Lachmann
 Advances in Chronic Kidney Disease,Volume 19, Issue 5 , Pages 287-290,September 2012 25-hydroxyvitaminDdeficiency,exacerbationfrequencyandhuman rhinovirus exacerbations in chronic obstructive pulmonary disease. Quint JK, Donaldson GC, Wassef N, Hurst JR, Thomas M, Wedzicha JA. BMC Pulm Med. 2012 Jun 22;12:28.doi: 10.1186/1471-2466-12-28. Utility of the Heavy Light Chain (HLC) assay in patients with AL amyloidosis with a detectable serum monoclonal protein Ashutosh D Wechalekar, Philip Young, Nancy Wassef, Julian D Gillmore, Simon DJ Gibbs,Jennifer H Pinney, Christopher P Venner, Darren Foard, Lisa Rannigan,Thirusha Lane, Carol J Whelan, Helen J Lachmann, Arthur Bradwell, Stephen Harding and Philip N HawkinsPoster in the Proceedings of XIIIth International Symposium on Amyloidosis, Gronenberg, NL, May 2012 Normalheavy/lightchain(HLC)andfreelightchain(FLC)ratiosare associated with prolonged survival in patients with systemic AL amyloidosis Ashutosh D Wechalekar, Philip Young, Nancy Wassef, Julian D Gillmore, Simon DJ Gibbs,Jennifer H Pinney, Christopher P Venner, Darren Foard, Lisa Rannigan,Thirusha Lane, Carol J Whelan, Helen J Lachmann, Arthur Bradwell, Stephen Harding and Philip N Hawkins Poster in the Proceedings of XIIIth International Symposium on Amyloidosis, Gronenberg, NL, May 2012
  12. 12. Dr. Nancy L. Wassef | Curriculum Vitae Page 12 Natural history of wild type transthyretin amyloidosis and possibility of developing an algorithm to differentiate it from isolated cardiac AL amyloïdosis Pinney, Jennifer H.,Whelan, Carol J. , Petrie, Aviva , Dungu, Jason, Banyperasad, Sanjay M.,Sattianayagam, Prayman, Wechalekar, Ashutosh D., Gibbs, Simon D.J., Venner, Christopher P.,Wassef, Nancy McCarthy, Carolyn M., Gilbertson, Janet A., Hunt, F. Toby, Rowczenio,Dorota M., Hawkins, Philip N., Gillmore, Julian D.1, Lachmann, Helen J. Poster in the Proceedings of XIIIth International Symposium on Amyloidosis, Gronenberg, NL, May 2012 18. Light chain deposition disease: improved patient survival in the era of novel agents Simon DJ Gibbs, Jennifer H Pinney, Julian D Gillmore, Agata Grasso, Andrew Jabbour, Janet A, Gilbertson, Prayman T Sattianayagam, Christopher P Venner, Jason Dungu, Sanjay M,Banypersad, Carol J Whelan, Dorota M Rowczenio, Nancy L Wassef, Ashutosh D Wechalekar, Arthur R Bradwell, Philip N Hawkins and Helen J Lachmann Poster in the Proceedings of XIIIth International Symposium on Amyloidosis, Gronenberg, NL, May 2012 Outcome in Renal AL Amyloidosis following Chemotherapy
 Jennifer H. Pinney, Helen J. Lachmann, Loveleen Bansi, Ashutosh D. Wechalekar, Janet A. Gilbertson, Dorota Rowczenio, Prayman T. Sattianayagam, Simon D.J. Gibbs, Emanuela Orlandi, Nancy L. Wassef, Arthur R. Bradwell, Philip N. Hawkins and Julian D. Gillmore JCO Feb 20, 2011:674-681 Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis Ashutosh D. Wechalekar, Julian D. Gillmore,Nancy Wassef, Helen J. Lachmann, Carol Whelan and Philip N. Hawkins 
 Letter to the Editor, Haematologica 2011,96(7) 
 Transient increases in NT pro-BNP concentration during chemotherapy for AL amyloidosis are associated with inferior long-term survival 
 Simon Gibbs, Prayman Sattianayagam, Jennifer Pinney, Carol Whelan, Jason Dungu, Marna De Cruz, Helen Lachmann, Nancy Wassef, Julian Gillmore, Philip Hawkins, Ashutosh Wechalekar 
 MS ID#: BLOOD/2011/361105 
 Validation of DFLC Method for Monitoring Clonal Responses in Systemic AL Amyloidosis: Superior outcome of patients achieving >90% Response (VGPR). S. Gibbs, P. Sattianayagam, J. Gillmore, J. Pinney, N. Wassef, M. Offer, J. Gilbertson, D. Rowczenio, T. Lane, C. Whelan, J. Dungu, A. Bradwel, H. Lachmann, P. Hawkins, A.Wechalekar 13th International Myeloma Workshop, Paris 3-7 May,2011 Effects of Time Outdoors And Hours of Day Light on Vitamin D Level In COPD Jennifer K. Quint, Gavin C. Donaldson, James J. Goldring, John R. Hurst, Nancy Wassef, Mike Thomas, Jadwiga A. Wedzicha
 Conference Paper:American Thoracic Society 2011 International Conference, May 13-18,2011• DenverColorado;05/2011 103 Senile systemic amyloidosis: a common cause of heart failure in the elderly? J H Pinney, H J Lachmann, J D Gillmore, A Wechalekar, S D J Gibbs, P Sattianaagam, S M Banypersad, J Dungu, N Wassef, C A McCarthy, P N Hawkins, C J Whelan Heart 2011;97:A59-A60 doi:10.1136/heartjnl-2011-300198.103 An analysis of the endocrine disease associated with systemic AL Amyloidosis Gibbs, S, Vanderpump, M.P., Hutt, D,Sattianayagam, P, Pinney, J, Wassef N ,Gillmore, J, Lachmann, H, Hawkins, P, Wechalekar,A Wednesday, 06 May 2015 15th Congress of the European Hematology Association, Paris,France, September 2010 Amyloidosis in patients with gastrointestinal neuromuscular disorder of the gut ( GINMD) - comparison of serum and histopathological diagnostic techniques D.Chowdhury, N Wassef, A. Raimundo, A. Darzi , J. Martin, D.B.A. Silk DDW 2010 by American Gastroenterology association, USA Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis Ashutosh Wechalekar, Stephen Harding, Helen Lachmann, Julian Gillmore, Nancy Wassef, Michael Thomas, Gibbs SDJ, Sattianayagam P, Whelan CJ, Arthur Bradwell and Philip Hawkins XII International Amyloidosis Symposium, Rome, Italy,
  13. 13. Dr. Nancy L. Wassef | Curriculum Vitae Page 13 April 2010. A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT- ProBNPAshutosh D Wechalekar, Nancy L Wassef, Simon DJ Gibbs, Julian Gillmore, Felicia Dike, Helen Lachmann, Prayman Sattianayagam, Arthur Bradwell and Philip N Hawkins 51 st ASH Annual Meeting, New Orleans, USA, December 2009. High early mortality and poor outcomes for patients with AL amyloidosis having high presenting serum free light chains – a new risk stratification model D Wechalekar, Nancy Wassef, Julian D Gillmore, Simon Gibbs, Prayman Sattianayagam, Helen J Lachmann, Philip N Hawkins, 14th Congress of the European Hematology Association, Berlin, Germany, June 2009 Monoclonal protein detection in AL amyloidosis revisited - analysis of 642 patients N L Wassef, JD Gillmore, HJ Lachmann, J Morris, M Thomas, AR Bradwell, G Mead, PN Hawkins, AD Wechalekar XII International Myeloma Workshop, Washington, D.C., USA, February 2009. Monoclonal protein detection in AL Amyloidosis re-visited. Analysis of 644 patients N L Wassef, JD Gillmore, HJ Lachmann, J Morris, M Thomas, AR Bradwell, G Mead,PN Hawkins, AD Wechalekar. 5th Euramy Meeting, Portugal, October 2008 Vitamin D levels and susceptibility to human rhinovirus exacerbations of COPD JK Quint, GC Donaldson, JJP Goldring, A Patel, S Karmali, N Wassef, M Thomas, JA Wedzicha British Thoracic Society meeting, London, UK, December 2009. Thyroid dysfunction in a Hepatitis C population treated with Interferon and Ribavirin Combination Therapy in a UK cohort.
 
 Costelloe, Seán; Wassef, Nancy; Josephine, Schulz; Vaghjiani, Tina; Whiting, S; Thomas, Michael;Dusheiko, Geoffrey; Jacobs, Michael; Vanderpump, Mark .2009 Vitamin D deficiency does not affect FEV1 decline in chronic obstructive pulmonary disease J K Quint, G C Donaldson, JJP Goldring, N Wassef, M Thomas and J A Wedzicha European Respiratory Society Conference, Vienna, Austria, September 2009. Vitamin D deficiency does not affect exacerbation frequency in chronic obstructive pulmonary disease J K Quint, G C Donaldson, JJP Goldring, N Wassef,M Thomas and J A WedzichaEuropean Respiratory Society Conference, Vienna, Austria, September 2009. An audit of thyroid dysfunction in a Hepatitis C population treated with Interferon and Ribavirin at the Royal Free Hospital. S J Costelloe, N Wassef, C Morris, J Schulz, T Vaghijiani, S Whiting, M Thomas, G Dusheiko, M Jacobs, M Vanderpump Poster in the Proceedings of FOCUS Meeting, Liverpool, UK, May 2009. Thyroid dysfunction in a Hepatitis C population treated with Interferon therapy S J Costelloe, N Wassef, C Morris, J Schulz, T Vaghijian, M Thomas, G Dusheiko, M Jacobs, M Vanderpump British Endocrine Society meeting, Harrogate, March, 2009. PRESENTATIONS ❖ Plasma Cell Dyscrasias and Electrophoresis, Egyptian Society of laboratory Medicine International Conference,Cairo, April 2015 Helena Distrubutors Training Day, February 2015 ❖ Haemoglobinopathies and Haemoglobin Electrophoresis, Egyptian Society of laboratory Medicine International
  14. 14. Dr. Nancy L. Wassef | Curriculum Vitae Page 14 Conference, Cairo, April 2015 ❖ Immunofixation and Immunodisplacement Training, UGM Staff, Cairo, April 2015 Sysmex Staff, Netherland, March 2015 Helena Education Day, Newcastle, March 2015 ❖ The Importance of Both: Electrophoresis and Free Light Chain Assay Helena International Users Group meeting, Barcelona, September 2014 ❖ Amyloidosis in the UK Sebia User Group, Birmingham, September 2014 ❖ Amyloidosis in UK, Egyptian Society of laboratory Medicine International Conference, Cairo, April 2014 Wednesday, 06 May 2015 All Supporting Evidences and Reference letters supplied. ❖ Pitfalls of Electrophoresis Egyptian, Society of laboratory Medicine International Conference, Cairo, April 2014 ❖ Using Electrophoresis as a Diagnostic Tool: Clinical Case Studies, Arab Health Exhibition Dubai, January 2014, organised by Helena Biosciences Europe ❖ Laboratory Perspective in Diagnosing and Monitoring Plasma Cell Dyscrasias, Helena Electrophoresis Education day, Royal College of Pathologists, November 2013 ❖ Amyloidosis in the UK, Helena International User Group, Paris, October 2013 ❖ A case study: Myeloma case Journal Club, Royal Free Hospital, London, March 2013 ❖ Unexpected Haemoglobin A1c Results Journal Club, Royal Free Hospital, London, June 2011 ❖ The Demise of BJP or Not? How the audit was conducted, Royal Free Hospital, London, June 2007 ❖ Glycated Haemglobin, pitfalls in its determination, Royal Free Hospital, London, April 2007 PERSONAL INFORMATION Trilingual: Fluent in French, English and Arabic Nationality: British Interests: ▪ Alternative complementary medicine and healing techniques. ▪ Reading about different cultures and philosophy books ▪ Charities and social events organising.

×